Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.
Researchers call for closer cardiovascular monitoring for those switching from the TDF form of the drug to the TAF version.
Gilead Sciences has released multiple combo tablets that contain the updated tenofovir, which is linked to improved bone and kidney makers.
Researchers compared switching to Symtuza with staying on an effective regimen of a boosted protease inhibitor plus Truvada.
The single-tablet antiretroviral regimen includes Janssen’s darunavir plus Gilead’s cobicistat, emtricitabine and tenofovir alafenamide.
That’s compared with HIV-negative men.
A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.
In a randomized comparison trial, those who switched from Epzicom to Descovy had a comparable rate of HIV suppression.
The once-daily regimen includes the integrase inhibitor bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).
A new large study compared the single-tablet regimen with an equivalent containing a different version of tenofovir.
Compared with the older tenofovir, called TDF, the new one, TAF, suppressed the virus as well and offered bone, kidney and lipid benefits.
A tablet containing bictegravir and the contents of Descovy suppressed HIV as well as boosted protease inhibitor regimens.
The combo tablet contains Janssen’s darunavir and Gilead Sciences cobicistat, emtricitabine and tenofovir alafenamide.
HIV-positive people 50 and older who switched from Truvada to Descovy in a recent trial reaped health benefits.
The U.S. Food and Drug Administration approved Gilead Sciences’ Descovy for the treatment of HIV in combination with other antiretrovirals.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.